(Q38447421)

3 September 2017

title

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients (English)

1 reference

3 September 2017

1 reference

1 reference

1 reference

S Wilgenhof

1

1 reference

3 September 2017

A M T Van Nuffel

2

1 reference

3 September 2017

D Benteyn

3

1 reference

3 September 2017

J Corthals

4

1 reference

3 September 2017

C Aerts

5

1 reference

3 September 2017

C Heirman

6

1 reference

3 September 2017

I Van Riet

7

1 reference

3 September 2017

A Bonehill

8

1 reference

3 September 2017

K Thielemans

9

1 reference

3 September 2017

B Neyns

10

1 reference

3 September 2017

publication date

31 July 2013

1 reference

3 September 2017

1 reference

3 September 2017

volume

24

1 reference

3 September 2017

issue

10

1 reference

3 September 2017

page(s)

2686-2693

1 reference

Human T cell responses against melanoma

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Cancer immunotherapy via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Engineering dendritic cells to enhance cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Dendritic cell vaccines in melanoma: from promise to proof?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT245

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT245

1 reference

3 September 2017

1 reference